Publications by authors named "M T Tees"
We analyzed access barriers to anti-CD19+ chimeric antigen receptor T-cells (CART) for non-Hodgkin lymphoma (NHL) within a community-based transplant and cell therapy network registry. 357 intended recipients of FDA-approved anti-CD19+ CART were identified in the study period (2018 to 2022). Results showed that the median age at referral was 61 years, referral year was 2018 (4%), 2019 (14%), 2020 (18%), 2021 (26%), and 2022 (38%).
View Article and Find Full Text PDFArticle Synopsis
- Myasthenia gravis (MG) is a disease where the body's immune system mistakenly attacks the nerves, making it hard for muscles to work properly, and researchers tested a high-dose chemotherapy treatment on a patient with severe MG who didn’t get better with other treatments.
- The patient received chemotherapy and a procedure to help her immune system recover, and after this treatment, she started feeling better really quickly and stayed symptom-free for a long time.
- The study suggests that this new treatment may help some people with severe MG, and there's interest in doing more research to see if it works for others with the same problem.
Article Synopsis
- Some doctors are debating whether to change treatment for Hodgkin Lymphoma patients who still have cancer after two cycles of ABVD therapy.
- Researchers looked at data from 15 hospitals to see how many patients with positive PET scans switched their treatment between 2015 and 2019.
- They found that not many patients changed their treatment, and results showed that those who did aren’t always getting better, so better ways to treat these patients are needed.
Maintenance Therapies in Indolent Lymphomas: should Recent Data Change the Standard of Care?
Curr Treat Options Oncol
March 2017
The overall benefit of maintenance therapy for patients with an indolent lymphoma continues to go unanswered. A myriad of variables contribute to the lack of clear clinical guidance. First, the disease course is slow and treatment may not be required for years, requiring a long follow-up to prospectively study.
View Article and Find Full Text PDFChronic lymphocytic leukemia and small lymphocytic lymphoma: two faces of the same disease.
Expert Rev Hematol
February 2017
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are considered indolent lymphocytic malignancies, more often requiring active surveillance rather than intervention. Despite the indolent nature of CLL/SLL, treatment is likely indicated in a patients' lifetime. Recent changes in the therapeutic landscape have created more options to the clinician.
View Article and Find Full Text PDF